Clinical Trials on Complement System; Disorder

Total 10000 results

CSL Behring

Completed

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement-mediated Disorders

Australia
Longbio Pharma

Not yet recruiting

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

Complement-mediated Renal Diseases

China
Catalyst Biosciences

Terminated

Screening Study to Identify Patients With Complement Factor I Deficiencies

Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency

United States
Ankara City Hospital Bilkent

Completed

Endometriosis and Complement System

Endometriosis | Complement System | Alternative Complement Pathway

Turkey
University Medical Centre Ljubljana

Enrolling by invitation

Immune System in Diabetic Kidney Disease (KID-CODE)

Diabetes | Diabetic Kidney Disease | Complement System

Slovenia
Acibadem University

Completed

Comparison of Factor XII Levels in Gestational Diabetic and Healthy Pregnancies

Pregnancy Related | Diabetic Pregnancy | Complement System; Disorder

Turkey
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Netherlands, Spain, Switzerland, United Kingdom, Japan, Belgium, Israel, Argentina, South Korea
Apellis Pharmaceuticals, Inc.

Completed

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Switzerland, Austria, Italy, Czechia, Belgium, Argentina, Canada, Poland, South Korea
Apellis Pharmaceuticals, Inc.

Approved for marketing

C3G/Primary IC-MPGN EAP

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States
Nanjing Chia-tai Tianqing Pharmaceutical

Not yet recruiting

A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers

Complement-mediated Hemolytic Diseases

China
Heeger, Peter, M.D.
Icahn School of Medicine at Mount Sinai; Alexion Pharmaceuticals

Terminated

Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

Kidney Transplantation | Delayed Graft Function | Complement Activity

United States
Apellis Pharmaceuticals, Inc.

Completed

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, United Kingdom, Australia, Austria, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Institut Pasteur de Lille

Completed

Fish Collagen Peptide Food Supplement on Weight and Body Composition (NATICOL)

Weight Management | Food Complement

France
Nanjing Chia-tai Tianqing Pharmaceutical

Not yet recruiting

Effect of Food of NTQ5082 in Healthy Subjects

Complement-mediated Hemolytic Diseases

China
Chengdu Suncadia Medicine Co., Ltd.

Completed

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

Complement Mediated Primary or Secondary Glomerular Diseases

China
Chengdu Suncadia Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

Complement Mediated Primary or Secondary Glomerular Diseases

China
First Affiliated Hospital, Sun Yat-Sen University

Completed

The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer

Gastric Cancer | Surgery | Complement Component Deficiency

China
Novartis Pharmaceuticals

Not yet recruiting

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain (ROUTE-C3G)

Complement 3 Glomerulopathy
Fondazione Policlinico Universitario Agostino Gemelli...

Withdrawn

Lectine Pathway in Unstable Carotid Plaque

Carotid Artery Plaque | Mannose-Binding Lectin Complement Pathway
Chengdu Suncadia Medicine Co., Ltd.

Completed

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

Hemolytic Anemia | Complement Mediated Glomerular Diseases

China
University of Oxford
Wellcome Trust

Completed

Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases (C2)

Complement Mediated Bacterial Killing in Healthy Adults

United Kingdom
Novartis Pharmaceuticals

Not yet recruiting

CHART-C3G/CLNP023B12011

Proteinuria | C3 Glomerulopathy | Complement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd.

Recruiting

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

Complement-mediated Kidney Disease | Paroxysmal Nocturnal Hemoglobinuria, PNH

China
Amyndas Pharmaceuticals S.A.

Completed

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Complement Mediated Diseases

United States
Cedars-Sinai Medical Center
Alexion Pharmaceuticals, Inc.

Terminated

Complement Regulation to Undo Systemic Harm in Preeclampsia (CRUSH)

Pregnancy Related | Preeclampsia | HELLP Syndrome | Severe Preeclampsia | HELLP | Complement Regulatory Factor Defect | PNH | Eculizumab | HELLP Syndrome Second Trimester | AHUS | Complement Abnormality | HELLP Syndrome Third Trimester

United States
ADARx Pharmaceuticals, Inc.

Recruiting

Chinese Adults With Kidney Disease

IC-MPGN | Complement 3 Glomerulopathy (C3G) | Immunoglobulin A Nephropathy (IgAN)

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia

Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)

China
Takeda

Recruiting

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia

Hereditary Angioedema (HAE)

Saudi Arabia
CSL Behring

Available

Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study

Hereditary Angioedema (HAE)
Ionis Pharmaceuticals, Inc.

Recruiting

Donidalorsen Treatment in Children With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Italy, Spain, Poland
Takeda
CRO Axelys Santé DZ

Recruiting

A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema (AHAE)

Hereditary Angioedema (HAE)

Algeria
Takeda

Recruiting

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

Hereditary Angioedema (HAE)

France, Israel, Serbia, Germany, United Kingdom, Argentina
University Hospital, Lille
CSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; Oc... and other collaborators

Completed

Systematic Search for Primary Immunodeficiency in Adults With Infections (SPIDAC)

Pneumococcal Infections | Pneumonia, Bacterial | Meningitis, Bacterial | Otitis Media | Chronic Sinus Infection | Streptococcal Infection | Antibody Deficiency | Complement Deficiency | Neisseria Infections | Haemophilus Influenza

France
ADARx Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgAN | C3G | IC-MPGN | IgA Nephropathy (IgAN) | Complement-mediated Kidney Disease

United States, Australia, Hong Kong, South Korea, Spain, United Kingdom
BioCryst Pharmaceuticals

Terminated

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
Nang Kuang Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema

Hereditary Angioedema (HAE) | Bradykinin-mediated Angioedema

Taiwan
Takeda

Not yet recruiting

A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea

Hereditary Angioedema (HAE)
Takeda

Not yet recruiting

A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt (EXPLORHAE)

Hereditary Angioedema (HAE)

Egypt
Astria Therapeutics, Inc.

Enrolling by invitation

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Spain, United States, Hong Kong, Brazil, Bulgaria, Canada, Germany, Israel, Japan, Netherlands, North Macedonia, Poland, South Africa, United Kingdom
KalVista Pharmaceuticals, Ltd.

Available

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Hereditary Angioedema

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (IMPROVE)

Kidney Transplant

United States
Q32 Bio Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

IgA Nephropathy | Lupus Nephritis (LN) | C3 (Complement Component 3) Glomerulopathy

United States
Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Genetic Disorders | Angioneurotic Edema

Netherlands, Romania
Istituti Clinici Scientifici Maugeri SpA

Recruiting

Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema (REAL-HAE)

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2

Italy
University Hospital, Catania

Unknown

Hereditary AngioEdema, Neurobiology and Psychopathology (HAENP)

Depression | Anxiety | Hereditary AngioEdema

Italy
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
University Hospital, Grenoble

Completed

Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema (BESQAOH)

Hereditary Angioedema

France
Region Skane

Recruiting

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis | Complement Abnormality

Sweden

Clinical Trials on Complement System; Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations